BioSpace News Archive

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.

Through their work, they were able to determine that the protein, TAp63, appears to impact the level of RNA molecules within the body. This subsequently connects the activities of p53 and AKT, the altered genes in cancer.

Kite, a Gilead company, is building a franchise, not just a brand, on the promise of its CAR-T cell therapies.

With an initial capital of $50 million, MD Anderson and partner The Focus Fund hope to invest in small biotechs with big cancer-fighting potential.

Under terms of the Korsuva deal, Connecticut-based Cara Therapeutics will receive $100 million in an upfront payment, as well as an equity investment of $50 million. Additional milestone payments could bring the total of the deal to about $290 million.

INCOG BioPharma Services, is a biopharmaceutical manufacturing services startup that will be establishing a manufacturing plant soon. You can get more details here.

In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.

Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine.

Shares of Aptinyx skyrocketed more than 75% after the company reported its mid-stage experimental treatment for post-traumatic stress disorder demonstrated clinically meaningful and statistically significant results that will set up a pivotal study next year.

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, launched Don’t Let Pain Gain on You, a multimedia campaign to inform and empower people who have delayed joint replacement surgery to have a conversation with their healthcare professional about confidently moving forward with their procedure.